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Introduction 
Hydroxyurea is a chemotherapeutic agent used in 
the treatment of various hematological diseases, 
most commonly chronic myelogenous leukemia, 
polycythemia vera, and sickle cell anemia [1]. It is also 
used to treat psoriasis [2]. Hydroxyurea blocks DNA 
synthesis and cellular division by inhibiting 
ribonucleoside reductase [3]. Numerous cutaneous 
side effects have been observed with hydroxyurea 
administration including xerosis, dermal ulcers, 
dermatomyositis-like eruptions, and hyperpigmentation 
[4]. Hyperpigmentation has been observed in the 
oral mucosa, nails, and in a diffuse pattern [1, 3]. 
Diffuse hyperpigmentation related to hydroxyurea is 
thought to be correlated with increased melanin [5]. 
We report a novel case in which hydroxyurea 
hyperpigmentation exhibited iron deposition. 
 
Case Synopsis 
A 75-year-old man with a history of myelodysplastic 
syndrome presented to the dermatology clinic with 
a one-year history of progressive darkening of his 
lower legs. The patient denied a history of trauma 
and other associated symptoms including pruritus 
and pain. There had been no preceding edema or 
hyperpigmentation. He had been taking 
hydroxyurea for several weeks prior to the onset of 
the hyperpigmentation. Other medications included 
garlic tablets, levothyroxine, “Liver Defense” tablets, 
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used in the treatment of various hematological 
diseases including chronic myelogenous leukemia, 
polycythemia vera, and sickle cell anemia. 
Hydroxyurea is also used to treat psoriasis. Drug-
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Figure 1. Drug-induced hyperpigmentation. Well-demarcated 
violaceous to hyperpigmented confluent patches on bilateral 
distal lower extremities.
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multivitamin tablets, NutriFeron immunity 
supplement, Vitamin B complex, Vitamin D3, and 
Vitamin E.  
Physical examination revealed well-demarcated 
violaceous to hyperpigmented confluent patches on 
his distal lower extremities bilaterally (Figure 1). 
There was no pigment deposition in the nails or the 
mucosa. The conditions in the differential diagnosis 
included ecchymosis, hydroxyurea-induced 
hyperpigmentation, and angiosarcoma. 
A punch biopsy from the right lateral shin showed a 
slightly atrophic epidermis with increased number of 
venules throughout the dermis and extension into 
the subcutaneous tissue. Extravasated erythrocytes 
from venules and small capillaries were seen with 
yellow-brown pigment. Perls stain was positive, 
whereas Fontana-Masson was negative, which is 
consistent with hemosiderin (Figure 2). Scanning 
Electron Microscopy/Energy Dispersive x-ray 
Spectroscopy (SEM/EDS) analysis of the pigment 
deposits was consistent with endogenous iron 
deposition (Figure 3). The patient’s final diagnosis 
was hydroxyurea-induced hyperpigmentation 
related to dermal iron deposition. 
The patient was continued on hydroxyurea given its 
benefit in managing his myelodysplastic syndrome. 
At follow up, the patient reported the eruption had 
continued to remain asymptomatic and had not 
spread further. 
 
Case Discussion 
Drug-induced hyperpigmentation (DIH) is a known 
cutaneous side effect of hydroxyurea. Sites of DIH 
involvement include the oral mucosa, the nail plates, 
and a generalized or diffuse cutaneous pattern [1, 3]. 
Involvement of the nail plates can involve the entire 
nail plate or present as longitudinal or transverse 
bands [1]. The incidence of hydroxyurea-induced 
hyperpigmentation has been reported to be as high 
as 50 % [6]. Drug-induced hyperpigmentation has 
been seen as early as 7 weeks to several years after 
initiating hydroxyurea treatment [7]. 
The clinical types of DIH can be classified as: 
Type I: black-blue pigmentation in pre-existing scars 
 
 
 
 
Figure 2. Drug-induced hyperpigmentation. A punch biopsy 
from a pigmented area on the right lateral shin showed an 
increased number of venules throughout the dermis extending 
into the subcutaneous tissue along with extravasated 
erythrocytes and yellow-brown pigment, and a positive Perls 
stain for iron (see arrow). H&E A) 100×, B) 400×; C) Perls stain 
400×.
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Type II: blue-grey pigmentation on shins and 
forearms 
Type III: diffuse muddy-brown discoloration in sun-
exposed areas 
These clinical types have been classically reported 
with minocycline DIH. Drug-induced 
hyperpigmentation clinical types I and II are 
associated with iron deposition in the dermis [8]. 
Analysis of cutaneous minocycline pigmentation has 
shown high levels of iron chelated to a minocycline 
metabolite that is stored within the lysosomes of 
macrophages [9]. 
Our patient’s DIH was consistent with a type II 
pattern. Similar to minocycline type II DIH in which 
the shins are the most commonly involved area and 
histologically the pigment is often found 
perivascularly, this patient presented with lower 
extremity involvement including the shins and the 
histopathology showed the pigment was located in 
the perivascular region [10]. Furthermore, we 
conclusively demonstrated iron deposition within 
the dermis. Therefore, using the minocycline-
associated pigment analogy, a proposed 
pathogenesis of a subset of hydroxyurea DIH could  
 
Figure 3. A) Scanning electron microscopic low magnification backscatter electron image of the deep dermis showing brighter 
inorganic particles with higher density than the underlying tissue. B) Higher magnification of the boxed area in (A) with particle analyzed 
(yellow arrow). C) Energy dispersive X-ray spectroscopic image of the particle showing composition of hemosiderin (Fe, P and S). No 
unusual minerals or metals were observed. 
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be postulated as hydroxyurea or its metabolite 
forming a complex with iron. However, this possible 
hypothesis is limited by the lack of a control biopsy 
from normal appearing skin. More cases and further 
studies would be needed to prove this proposed 
mechanism.   
 
Conclusion 
This case report demonstrates that hydroxyurea or 
its metabolite can possibly form a complex with iron 
in hydroxyurea-induced hyperpigmentation. The 
biopsy from the patient’s shin showed a negative 
Fontana-Masson stain, but SEM/EDS analysis was 
consistent with iron deposition. Furthermore, 
histopathology showed that the pigment was 
located in the perivascular region similar to 
minocycline type II DIH. The proposed mechanism of 
hydroxyurea or its metabolite forming a complex 
with iron will require further studies. 
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